The stock of Cempra Inc (NASDAQ:CEMP) is a huge mover today! About 1.21 million shares traded hands. Cempra Inc (NASDAQ:CEMP) has declined 64.61% since April 14, 2016 and is downtrending. It has underperformed by 69.30% the S&P500.
The move comes after 9 months negative chart setup for the $341.64 million company. It was reported on Nov, 16 by Barchart.com. We have $5.55 PT which if reached, will make NASDAQ:CEMP worth $44.41 million less.
Cempra Inc (NASDAQ:CEMP) Ratings Coverage
Out of 12 analysts covering Cempra (NASDAQ:CEMP), 3 rate it a “Buy”, 2 “Sell”, while 7 “Hold”. This means 25% are positive. Cempra has been the topic of 23 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock has “Mkt Perform” rating given by Leerink Swann on Tuesday, October 13. The rating was maintained by Roth Capital with “Buy” on Tuesday, June 7. The rating was downgraded by Morgan Stanley to “Underweight” on Tuesday, November 8. Needham downgraded Cempra Inc (NASDAQ:CEMP) on Sunday, November 13 to “Hold” rating. Needham maintained the stock with “Buy” rating in Monday, November 7 report. The stock of Cempra Inc (NASDAQ:CEMP) earned “Buy” rating by Needham on Thursday, July 30. Raymond James downgraded the stock to “Market Perform” rating in Wednesday, November 2 report. The company was downgraded on Friday, November 11 by Needham. As per Monday, November 7, the company rating was downgraded by Jefferies. The stock of Cempra Inc (NASDAQ:CEMP) has “Buy” rating given on Friday, December 11 by Janney Capital.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.27 in Q2 2016. Its up 0.72, from 1.55 in 2016Q1. The ratio is positive, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
Public Employees Retirement Association Of Colorado reported 12,384 shares or 0% of all its holdings. Proshare Advsr Limited Com holds 40,947 shares or 0.01% of its portfolio. Great West Life Assurance Can last reported 4,801 shares in the company. Perceptive Limited Company last reported 0.19% of its portfolio in the stock. Cna Financial holds 0.15% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 35,472 shares. Utd Svcs Automobile Association holds 0.01% or 120,700 shares in its portfolio. Royal Comml Bank Of Canada has 617 shares for 0% of their US portfolio. Creative Planning has 950 shares for 0% of their US portfolio. Wasatch reported 2.43M shares or 0.61% of all its holdings. Timessquare Capital Management Limited Liability holds 0.22% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 2.05M shares. American Century Cos has 56,412 shares for 0% of their US portfolio. The New York-based Knoll Capital Mgmt Lp has invested 0.97% in Cempra Inc (NASDAQ:CEMP). Moreover, Ontario Teachers Pension Plan Board has 0.16% invested in Cempra Inc (NASDAQ:CEMP) for 854,564 shares. Teacher Retirement Of Texas owns 5,370 shares or 0% of their US portfolio. Acuta Capital Prns Limited Liability Company accumulated 1.66% or 210,000 shares.
More notable recent Cempra Inc (NASDAQ:CEMP) news were published by: Fool.com which released: “Why Cempra Inc Fell Over the Last 2 Days” on November 08, 2016, also Businesswire.com with their article: “Robbins Arroyo LLP: Cempra, Inc. (CEMP) Misled Shareholders According to a …” published on November 15, 2016, Fool.com published: “Why Cempra Inc. Got Crushed Again” on November 02, 2016. More interesting news about Cempra Inc (NASDAQ:CEMP) were released by: Fool.com and their article: “Why Cempra Inc Got Crushed Today” published on October 28, 2016 as well as Globenewswire.com‘s news article titled: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cempra, Inc …” with publication date: November 15, 2016.
CEMP Company Profile
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.